Cargando…

S146. EFFECT OF CLOZAPINE ON REGIONAL CEREBRAL BLOOD FLOW IN TREATMENT-RESISTANT SCHIZOPHRENIA

BACKGROUND: Approximately one-third of schizophrenia patients will not respond adequately to conventional antipsychotic treatment; termed treatment-resistant schizophrenia (TRS). The only antipsychotic recommended for this group is clozapine, which may have unique efficacy in improving residual symp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sendt, Kyra-Verena, McQueen, Grant, Gillespie, Amy, MacCabe, James, Zelaya, Fernando, Egerton, Alice
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5888012/ http://dx.doi.org/10.1093/schbul/sby018.933

Ejemplares similares

Biological Predictors of Clozapine Response: A Systematic Review
por: Samanaite, Ruta, et al.
Publicado: (2018)

T19. GLUTAMATE AND RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Egerton, Alice, et al.
Publicado: (2020)

Changes in Brain Glutamate on Switching to Clozapine in Treatment-Resistant Schizophrenia
por: McQueen, Grant, et al.
Publicado: (2021)

Subcortical volume reduction and cortical thinning 3 months after switching to clozapine in treatment resistant schizophrenia
por: Krajner, Fanni, et al.
Publicado: (2022)

M212. A SYSTEMATIC REVIEW AND META-ANALYSIS OF CLINICAL VARIABLES ASSOCIATED WITH RESPONSE TO CLOZAPINE IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Griffiths, Kira, et al.
Publicado: (2020)

O3.7. EFFECT OF N-ACETYLCYSTEINE ON BRAIN GLUTAMATE LEVELS AND RESTING PERFUSION IN SCHIZOPHRENIA
por: McQueen, Grant, et al.
Publicado: (2018)

Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia
por: McQueen, Grant, et al.
Publicado: (2018)

41. RECONSIDERING THE EVIDENCE FOR CLOZAPINE FOR TREATMENT REFRACTORY SCHIZOPHRENIA
por: MacCabe, James
Publicado: (2018)

Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? a systematic review
por: Gillespie, Amy L., et al.
Publicado: (2017)

Clozapine-induced agranulocytosis
por: Mijovic, Aleksandar, et al.
Publicado: (2020)

Effect of single dose N-acetylcysteine administration on resting state functional connectivity in schizophrenia
por: McQueen, Grant, et al.
Publicado: (2019)

Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland
por: Ingimarsson, Oddur, et al.
Publicado: (2016)

Clozapine Response in Schizophrenia and Hematological Changes
por: Blackman, Graham, et al.
Publicado: (2021)

Outcomes in treatment-resistant schizophrenia: symptoms, function and clozapine plasma concentrations
por: Krivoy, Amir, et al.
Publicado: (2021)

Clozapine and all‐cause mortality in treatment‐resistant schizophrenia: a historical cohort study
por: Cho, J., et al.
Publicado: (2018)

Risk of readmission in patients with schizophrenia and schizoaffective disorder newly prescribed clozapine
por: Kesserwani, Jad, et al.
Publicado: (2019)

Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study
por: Millgate, Edward, et al.
Publicado: (2022)

The lived experience of clozapine discontinuation in patients and carers following suspected clozapine-induced neutropenia
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Effects of Antipsychotic Administration on Brain Glutamate in Schizophrenia: A Systematic Review of Longitudinal (1)H-MRS Studies
por: Egerton, Alice, et al.
Publicado: (2017)

41.3 COULD CLOZAPINE REDUCE VIOLENT OFFENDING?
por: Bhavsar, Vishal, et al.
Publicado: (2018)

Management of clozapine treatment during the COVID-19 pandemic
por: Gee, Siobhan, et al.
Publicado: (2020)

Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis
por: Taylor, David, et al.
Publicado: (2022)

Establishing the characteristics of an effective pharmacogenetic test for clozapine-induced agranulocytosis
por: Verbelen, M, et al.
Publicado: (2015)

Clozapine treatment and risk of severe COVID‐19 infection
por: Ohlis, Anna, et al.
Publicado: (2021)

Clozapine treatment and risk of COVID-19 infection: retrospective cohort study
por: Govind, Risha, et al.
Publicado: (2021)

Prescribing clozapine in the UK: Quality improvement issues identified by clinical audit
por: Barnes, Thomas RE, et al.
Publicado: (2022)

Clozapine haematological monitoring for neutropenia: a global perspective
por: Oloyede, Ebenezer, et al.
Publicado: (2022)

Anterior cingulate glutamate metabolites as a predictor of antipsychotic response in first episode psychosis: data from the STRATA collaboration
por: Egerton, Alice, et al.
Publicado: (2022)

Neuroimaging Evidence for Cannabinoid Modulation of Cognition and Affect in Man
por: Bhattacharyya, Sagnik, et al.
Publicado: (2012)

Prevalence and Predictors of Clozapine-Associated Constipation: A Systematic Review and Meta-Analysis
por: Shirazi, Ayala, et al.
Publicado: (2016)

Reducing the Risk of Withdrawal Symptoms and Relapse Following Clozapine Discontinuation—Is It Feasible to Develop Evidence-Based Guidelines?
por: Blackman, Graham, et al.
Publicado: (2021)

S62. COGNITIVE DEFICITS IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Millgate, Edward, et al.
Publicado: (2020)

What are the barriers and facilitators of clozapine use in early psychosis? A survey of UK early intervention clinicians
por: Oloyede, Ebenezer, et al.
Publicado: (2023)

Reasons for discontinuing clozapine: A cohort study of patients commencing treatment
por: Legge, Sophie E., et al.
Publicado: (2016)

The physical health and side-effect monitoring of patients prescribed clozapine: data from a clinical audit conducted in UK mental health services
por: Barnes, Thomas R. E., et al.
Publicado: (2020)

Ethnic inequalities in clozapine use among people with treatment-resistant schizophrenia: a retrospective cohort study using data from electronic clinical records
por: de Freitas, Daniela Fonseca, et al.
Publicado: (2022)

Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
por: Sendt, Kyra-Verena, et al.
Publicado: (2012)

COVID-related hospitalization, intensive care treatment, and all-cause mortality in patients with psychosis and treated with clozapine
por: Govind, Risha, et al.
Publicado: (2022)

Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy
por: Segev, Aviv, et al.
Publicado: (2021)

USE OF CLOZAPINE IN CHILDHOOD SCHIZOPHRENIA
por: Srinivasan, T.N., et al.
Publicado: (1997)

Cannot write session to /tmp/vufind_sessions/sess_uug5aibf2b06um29nlus5citpn